Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | RBP4 | P02753 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.38 |
| ▸ | DPP4 | P27487 | 5/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
| ▸ | CPN1 | P15169 | 1/20 | 0.34 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.34 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10232869 | 1.00 | ALDH1A1 (0.41) | ALDH1A1MEN1KMT2ARBP4EPHX2 | |
| SCHEMBL15247298 | 0.87 | EPHX2 (0.42) | ALDH1A1MEN1KMT2AEPHX2DPP4 | |
| SCHEMBL15247297 | 0.87 | EPHX2 (0.42) | ALDH1A1MEN1KMT2AEPHX2DPP4 | |
| SCHEMBL22874688 | 0.87 | EPHX2 (0.42) | ALDH1A1MEN1KMT2AEPHX2DPP4 | |
| SCHEMBL15247215 | 0.86 | EPHX2 (0.39) | ALDH1A1MEN1KMT2ARBP4EPHX2 | |
| SCHEMBL22875185 | 0.84 | MEN1 (0.40) | ALDH1A1MEN1KMT2AEPHX2DPP4 | |
| SCHEMBL22874691 | 0.84 | MEN1 (0.40) | ALDH1A1MEN1KMT2AEPHX2DPP4 | |
| SCHEMBL22875187 | 0.84 | MEN1 (0.40) | ALDH1A1MEN1KMT2AEPHX2DPP4 | |
| SCHEMBL22874728 | 0.84 | MEN1 (0.40) | ALDH1A1MEN1KMT2AEPHX2DPP4 | |
| SCHEMBL26227925 | 0.84 | MEN1 (0.40) | ALDH1A1MEN1KMT2AEPHX2DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178744-A1 | FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178744-A1 | FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS | MTOR, RICTOR, RPTOR | ALDH1A1 4261/4885MEN1 948/4885KMT2A 1587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.